MedTrace Logo

uPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness

NCT03307460 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2020-11-23

No results posted yet for this study

Summary

Prospective study to evaluate the value of uPAR-targeted PET/MR scan using the tracer 68Ga-NOTA-AE105 in patients with newly diagnosed prostate cancer

Conditions

Interventions

DRUG

68Ga-NOTA-AE105

PET/MRI scan

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Marie Ø Fosboel, MD · Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-21
Primary Completion
2019-10-11
Completion
2022-04-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03307460 on ClinicalTrials.gov